Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of this study is to determine anti-tumor activity by measuring overall response rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and pembrolizumab.
Epistemonikos ID: da2fadd12fadd5410c1de03a3a1176ed0f294886
First added on: May 07, 2024